These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38031239)

  • 1. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
    Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.
    Bantounou MA; Sardellis P; Plascevic J; Awaes-Mahmood R; Kaczmarek J; Black Boada D; Thuemmler R; Philip S
    ESC Heart Fail; 2024 Sep; ():. PubMed ID: 39257196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
    Dos Santos Borges R; de Oliveira Almeida G; Alves VFC; Nienkotter TF; Bertoli ED; Simões E Silva AC
    J Nephrol; 2024 May; 37(4):881-896. PubMed ID: 38141092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
    Liu Y; An C; Liu P; Yang F; Zhao Q
    Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
    Stougaard EB; Rossing P; Vistisen D; Banks P; Girard M; Davies MJ; Persson F
    Diabetes Obes Metab; 2023 Jul; 25(7):1874-1882. PubMed ID: 36872068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Powell DR; Davies MJ; Banks P; Agarwal R
    Diabetes Obes Metab; 2023 Jun; 25(6):1646-1657. PubMed ID: 36782093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cao H; Rao X; Jia J; Yan T; Li D
    Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
    Sridhar VS; Bhatt DL; Odutayo A; Szarek M; Davies MJ; Banks P; Pitt B; Steg PG; Cherney DZI
    Clin J Am Soc Nephrol; 2024 May; 19(5):557-564. PubMed ID: 38277468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials.
    Bose D; Maurya M; Konwar M
    Indian J Pharmacol; 2023; 55(2):119-127. PubMed ID: 37313937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
    Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
    Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.
    Maddaloni E; Cavallari I; La Porta Y; Appetecchia A; D'Onofrio L; Grigioni F; Buzzetti R; Holman RR
    Diabetes Obes Metab; 2023 May; 25(5):1341-1350. PubMed ID: 36700422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Kakotrichi P; Michailidis T; Liakos A; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2022 Jan; 24(1):106-114. PubMed ID: 34545668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
    Sims H; Smith KH; Bramlage P; Minguet J
    Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials.
    Zhou F; Du N; Zhou L; Wang C; Ren H; Sun Q
    Front Endocrinol (Lausanne); 2022; 13():968478. PubMed ID: 36225203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
    Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.